Evidence map›Paper›PMID 41113653›Full record

ReviewFrontiers in microbiology2025

Endolysins: targeting

Giovanna Castallanos, Norberto Gonzalez-Juarbe, Daniel C Nelson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giovanna CastallanosInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, United States.
Norberto Gonzalez-JuarbeDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD, United States.
Daniel C NelsonInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, United States.

Funding

Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunityR01AI168313 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Norberto Gonzalez-Juarbe · 2023 to 2026
$3.5M
NIAID NIH HHS R01 AI168313
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bacteriophageendolysinmeningitisotitis mediapeptidoglycan hydrolasepneumoniasepsisStreptococcus pneumoniae

Identifiers

PMID41113653
PMCPMC12531234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.